The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Hanağasi
H A
HA
Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.
Kaptanoglu
G
G
Sahin
H A
HA
Emre
M
M
D000328:Adult; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000517:prevention & control*; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008559:Memantine / Q000008:administration & dosage / Q000627:therapeutic use*; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors*; D020734:Parkinsonian Disorders / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018691:Excitatory Amino Acid Antagonists; D007980:Levodopa; D016202:N-Methylaspartate; D008559:Memantine